Keros Therapeutics Q1 2026: A Long Cash Burn Turns a Corner—Perhaps, Not for the EBITDA Sprint

Overview: A Quarter Quiet on Revenue, Loud on Structure

Keros reported a net loss of $23.7 million for the first quarter of 2026, a reversal from a $148.5 million net income in Q1 2025. The swing is driven largely by the absence of large one-time revenue recognized in 2025 under the Takeda license agreement and the year-over-year reduction in R&D activity tied to the transition of elritercept-related costs to Takeda and a corporate restructuring completed in 2025.

There is no quarterly revenue figure disclosed for Q1 2026, a common asymmetry for clinical-stage biotechs with material upfront collaborations. The report does not publish an EPS figure either; for a company at this stage, the market often watches for revenue timing and cost structure more than a conventional earnings per share metric. In practice, that means the earnings surprise channel is muted here, and investors must read the tea leaves elsewhere—pipeline progress, partner funding, and cash runway.

Financials at a Glance

• Net loss: $23.7 million for Q1 2026, vs. net income of $148.5 million in Q1 2025. The delta reflects a mix of lower current-period revenue and reduced R&D activity.
• R&D expenses: $16.1 million in Q1 2026, down from $48.7 million in the prior-year period. The decline stems from the transition of elritercept-related R&D to Takeda and a 2025 corporate restructuring that streamlined spending.
• General and administrative (G&A) expenses: $10.1 million in Q1 2026, slightly down from $10.5 million in Q1 2025, aided by lower compensation costs post-restructuring.
• Cash and cash equivalents: $281.5 million as of March 31, 2026, down from $287.4 million at December 31, 2025. The company projects a cash runway into the first half of 2028 based on current operating assumptions.
• Pipeline and partnerships: Rinvatnercept and elritercept are central to the portfolio, with Takeda’s ongoing involvement shaping cost attribution and potential future milestones.

Context: What This Means for KROS and Peers

The quarter underscores a classic biotech-finance dynamic: the front-end burn is a function of the science ramp, collaboration financing, and corporate restructuring rather than cadence of quarterly revenue. The company’s note that cash runway extends into the first half of 2028 provides a window for continued development without immediate financing events, but it also elevates the importance of near-term catalysts—most notably, Takeda’s plan to advance elritercept into Phase 3 for anemia in myelofibrosis.

From the perspective of sector peers, this is a reminder that partnerships can materially reallocate development costs and accelerate or slow the burn rate depending on cash infusions, milestones, and cost-share arrangements. For investors, the big questions aren’t just “Will elritercept hit the Phase 3 mark?” but “How resilient is the cash runway if partner funding slows, or if a pipeline program encounters unexpected delays?”

Analysts will also weigh the absence of an EPS figure against the company’s strategic disclosures. In a world where EPS consensus is often a stock’s daily weather vane, Keros’ quarter asks investors to read beyond the line items and focus on the trajectory of the core partnership, the magnitude of non-dilutive funding (or lack thereof) from Takeda, and the potential revenue inflection from additional collaborations or licensing milestones.

The Portfolio, Rebalanced

Keros positions itself as a focused biopharma with two lead programs tied to TGF-β signaling biology: rinvatercept for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, and elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis. The company emphasizes its lead product candidate’s ongoing development, while acknowledging a shift of R&D cost responsibilities toward its Takeda partnership. This reallocation is a practical step in de-risking near-term capital needs, albeit with the caveat that success remains heavily contingent on clinical outcomes and regulatory milestones.

Outlook: What to Watch Next

Key items to monitor include: (1) Takeda’s execution on elritercept’s Phase 3 plan and any accompanying financial commitments; (2) updates on rinvatercept’s development timeline and potential expansion of indications; (3) any guidance on potential additional fundraising versus milestone inflows; (4) the durability of the cash runway beyond 2028 under various operating scenarios. Even without a disclosed EPS figure, the next several quarters will likely hinge on clinical momentum and partner-driven cost-sharing, rather than quarterly revenue sufficiency.

For sector peers, Keros’ experience highlights the importance of strategic collaborations in extending cash runway and focusing on high-priority indications. Biotech investors may start to scrutinize how a robust partner relationship can dampen the downside risk of clinical-stage volatility, while still leaving room for upside if pivotal data align with milestones.

Bottom Line

Keros’ Q1 2026 results are a reminder that in biotech, the art is often not about quarterly earnings surprises, but about the architecture around the pipeline: partnerships, restructuring, and cash planning. The company’s cash runway into mid-2028 is a valuable line in the sand, offering time to pursue Phase 3 catalysts and further collaboration logic. EPS and revenue numbers may be episodic in this space, but the strategic signals—partnership dynamics, cost discipline, and a pathway to value creation—are far from trivial for investors watching the TGF-β franchise and its peers.